Stock ATHA ATHIRA PHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Athira Pharma, Inc.

Equities

ATHA

US04746L1044

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-05 pm EDT 		5-day change 1st Jan Change
2.57 USD +4.90% Intraday chart for Athira Pharma, Inc. +0.78% +5.76%
May. 15 Athira Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 15 Athira Pharma, Inc. Appoints Javier San Martin, M.D., as Chief Medical Officer CI

Evolution of the average Target Price on Athira Pharma, Inc.

Price target over the last 5 years

History of analyst recommendation changes

8e6e63b9d3.iVLWsw4PTi3MQq47fxQs4WaKPVszSe1pilki19F0Q4c._wWi3n5XHUONEIMCG1NmiiD6WjgHA9Ug_y1S76NGDMHFGJTFPV49X6Ur6w~d8374402d77e120bb179882a4ec986a4

Analyst Recommendations on Athira Pharma, Inc.

JMP Securities Adjusts Athira Pharma Price Target to $19 From $20, Maintains Market Outperform Rating MT
Mizuho Cuts Price Target on Athira Pharma to $5 From $6, Reiterates Buy Rating MT
BTIG Adjusts Price Target on Athira Pharma to $10 From $33, Maintains Buy Rating MT
JMP Securities Upgrades Athira Pharma to Market Outperform From Market Perform; Price Target is $20 MT
Mizuho Securities Initiates Athira Pharma at Buy with $6 Price Target MT
Mizuho Initiates Athira Pharma With Buy Rating, $6 Price Target, Potentially 'Mis-Priced' Stock MT
Berenberg Bank Terminates Coverage of 85 Companies in Consumer Discretionary, Healthcare, Industrial Tech, REIT, Software and IT Services Sectors MT
Goldman Sachs Adjusts Price Target for Athira Pharma to $3 From $11, Maintains Neutral Rating MT
Stifel Nicolaus Downgrades Athira Pharma to Hold From Buy, Adjusts Price Target to $5 From $36 MT
JMP Securities Downgrades Athira Pharma to Market Perform From Market Outperform MT
Jefferies Downgrades Athira Pharma to Hold From Buy, Adjusts Price Target to $3 From $32 MT
BTIG Starts Athira Pharma at Buy With $33 Price Target MT
Berenberg Bank Initiates Coverage on Athira Pharma With Buy Rating, $33 Price Target MT
Goldman Sachs Reinstates Athira Pharma at Neutral With $16 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
2.57 USD
Average target price
7.275 USD
Spread / Average Target
+183.07%
High Price Target
19 USD
Spread / Highest target
+639.30%
Low Price Target
2.65 USD
Spread / Lowest Target
+3.11%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Athira Pharma, Inc.

JMP Securities
Mizuho Securities
BTIG
Jefferies & Co.
Stifel Nicolaus
Goldman Sachs
Berenberg Bank

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. ATHA Stock
  4. Consensus Athira Pharma, Inc.